Media coverage ArchivesSelect Year2024-20252023-20242022-202308 Oct 2024 FDA grants fast track designation to Wockhardt’s novel antibiotic WCK 6777 08 Oct 2024 USFDA grants fast track designation to Wockhardt novel antibiotic WCK 6777 07 Oct 2024 Wockhardt’s WCK 6777 earns Fast Track Designation from USFDA 07 Oct 2024 Wockhardt’s Innovative antibiotic receives FDA fast-Track Designation, stock surges 07 Oct 2024 Wockhardt’s WCK 6777 Receives Fast Track Designation by US FDA, Completes Phase I Study 07 Oct 2024 Wockhardt’s antibiotic gets Fast Track designation from USFDA 07 Oct 2024 Wockhardt’s once-a-day antibiotic drug ‘WCK 6777’ successfully concludes Phase I study 07 Oct 2024 US FDA grants fast track status to Wockhardt’s novel antibiotic WCK 6777 07 Oct 2024 Wockhardt’s new antibiotic WCK 6777 gains FDA fast track status, completes phase I trial, stocks decline 07 Oct 2024 WCK 6777 passes trials; FDA grants fast track status to antibiotic for complicated UTIs 04 Oct 2024 Dr Habil Khorakiwala honoured with Lifetime Achievement Award at 10th IHW summit 01 Oct 2024 Dr Habil Khorakiwala bags Lifetime Achievement Award at 10th Integrated Health C Wellbeing Summit in Dubai 27 Sept 2024 Wockhardt group Founder Chairman Dr Habil Khorakiwala bags Lifetime Achievement Award at 10th IHW summit in Dubai 27 Sept 2024 Dr. Habil Khorakiwala honoured with Lifetime Achievement Award 27 Sept 2024 Dr. Habil Khorakiwala Honored with Lifetime Achievement Award 26 Sept 2024 Dr Habil Khorakiwala honored with Lifetime Achievement Award 25 Sept 2024 Lifetime Achievement Award Presented to Dr. Habil Khorakiwala Wockhardt Founder 23 Sept 2024 Wockhardt’s Antibiotic Zaynich To Be Available In India At 80% Discount To US Price 23 Sept 2024 Wockhardt founder Dr. Habil Khorakiwala honored with lifetime achievement award 20 Sept 2024 Wockhardt targets global launch of new meningitis drug with $6 bn market potential by 2026 20 Sept 2024 Wockhardt’s Zaynich cures complex case of meningitis caused by pan-drug resistant super-bug under compassionate use 19 Sept 2024 Wockhardt’s investigational drug, Zaynich demonstrates its ability to manage complex infections 19 Sept 2024 Wockhardt’s investigational drug, Zaynich™ demonstrates its ability to manage complex infections 19 Sept 2024 India’s Wockhardt up after drug found effective in meningitis case 18 Sept 2024 Wockhardt Chairman Dr Habil Khorakiwala conferred with BIRAC Innovator Award 2024 18 Sept 2024 Wockhardt Chairman Dr Habil Khorakiwala conferred with BIRAC Innovator Award 2024 16 Sept 2024 Wockhardt clinches BIRAC innovator award for novel antibiotic 16 Sept 2024 BIRAC awards Wockhardt’s Chairman Dr Habil Khorakiwala for Nafithromycin innovation 16 Sept 2024 Wockhardt wins “BIRAC Innovator Award 2024” 3 Sept 2024 CDSCO Panel approves Wockhardt’s Protocol Amendment proposal for antimicrobial drug cefepime plus zidebactam 1 Jul 2024 Wockhardt soars as Zaynich shows promise against superbugs 1 Jul 2024 Wockhardt shares skyrocket 18% to fresh 52-week high. Here’s why? 1 Jul 2024 Multibagger stock! Wockhardt shares rally 16% to hit new 52-wk high; here’s why 1 Jul 2024 Wockhardt stock soars over 19% after its investigational antibiotic Zaynich successfully treats cancer patient in US 1 Jul 2024 Wockhardt soars as Zaynich shows promise against superbugs 1 Jul 2024 Why Wockhardt Share Price is Rising 1 Jul 2024 Wockhardt to Launch Antibiotic Zaynich with USD 25 Billion Market Potential 1 Jul 2024 Globally renowned US body CLSI awards high susceptibility breakpoints to Zaynich 1 Jul 2024 CLSI awards high susceptibility breakpoints to Zaynich 1 Jul 2024 US body Clinical and Laboratory Standards Institute (CLSI) awards high susceptibility breakpoints to Zaynich (Zidebactam/Cefepime- WCK 5222) 1 Jul 2024 Wockhardt On Future Growth Prospects, WCK 5222 & FY25 Product Pipeline | Dr. Habil Khorakiwala 1 Jul 2024 Wockhardt plans to launch antibiotic Zaynich in early FY26 30 Jun 2024 City pharma’s new antibiotic to combat superbugs by year-end 29 Jun 2024 Wockhardt Says Antibiotic Zaynich Showing Efficacy in Trials, Aims to Launch It by Early Financial Year 2026-2027 29 Jun 2024 Antibiotic Zaynich Showing Efficacy in Trials, Says Wockhardt Pharma 29 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26 29 Jun 2024 Wockhardt to Launch Groundbreaking Antibiotic Zaynich in India by 2025 29 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26 29 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 billion market potential by early FY26 28 Jun 2024 Wockhardt’s novel antibiotic Zaynich to be launched in India by end of FY25 28 Jun 2024 Wockhardt Launches New Antibiotic With $25-Billion Market Potential 28 Jun 2024 Wockhardt Launches New Antibiotic With $25-Billion Market Potential Manage your data 28 Jun 2024 Here’s why shares of Wochardt Pharma surged by 5% on Friday 28 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 billion market potential by early FY26 28 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26 28 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26 28 Jun 2024 Wockhardt Aims to Launch Billion-Dollar Antibiotic Zaynich by FY26 28 Jun 2024 Wockhardt’s novel antibiotic Zaynich to be launched in India by end of FY25 28 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 billion market potential by early FY26 28 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26 28 Jun 2024 Wockhardt likely to get DCGI nod for respiratory drug by year-end; stock up 5% 28 Jun 2024 Wockhardt claims breakthrough in drug-resistant infection in cancer patients with experimental drug Zaynich; US body awards highest susceptibility to the antibiotic 28 Jun 2024 Wockhardt’s investigational antibiotic shows significant effectiveness in global Phase 3 trials 28 Jun 2024 Here’s why shares of Wockhardt Pharma surged by 5% on Friday 28 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 billion market potential by early FY26 11 Mar 2024 Wockhardt announces success of antibiotic to treat drug-resistant infection 12 Jan 2024 Wockhardt has more antibiotics in the pipeline: Dr Habil Khorakiwala 14 Dec 2023 An antibiotics pipeline holds out promise for Wockhardt 11 Dec 2023 Wockhardt completes phase 3 study on Nafithromycin for pneumonia, shares surge 11 Dec 2023 Wockhardt shares zoom 19% to hit one-year high; here’s why 11 Dec 2023 Wockhardt shares surged by 14% today. How is it placed in the Pharma sector now 11 Dec 2023 Wockhardt completes Phase 3 pneumonia study of macrolide antibiotic Nafithromycin WCK 4873 11 Dec 2023 Wockhardt soars 19% on completion of phase-3 study of pneumonia drug 11 Dec 2023 Wockhardt shares hit 52-week high, rally over 18%; here’s why 11 Dec 2023 Wockhardt Stocks Hit Rs 398.95, a 52-Week High on Phase 3 Pneumonia Antibiotic Success 11 Dec 2023 Wockhardt Ltd Share surges 19 percent today sudden expert says stock may go up to Rs 450 19 July 2023 Journalistic Influence on Pharma Giants: Journalist Amelia Fernandes Joins Wockhardt’s Board 9 July 2023 Wockhardt charting a recovery riding on a promising new antibiotic 14 June 2023 Successful Use of WCK 5222 in an Adult Patient with Acute T-Cell Leukemia 31 Mar 2023 Wockhardt Aims For $12m Annual Savings Through US Restructuring22 February, 202322 Feb 2023 Wockhardt to restructure US business to save $12 million per year, sees debt pare down22 February, 202322 Feb 2023 At a turning point. Wockhardt in talks for vaccine manufacture in the UK22 February, 202321 Feb 2023 A Game-Changer: India’s Under-Trial Drug Shows Promise Against Hospital Superbugs21 February, 202312 Feb 2023 Under-trial antibiotic use saves minor thalassemia patient’s life12 February, 202313 Nov 2022 Desi antibiotic under trial in Europe saves woman’s life13 November, 202213 Nov 2022 Under-trial antibiotic cleared superbug infection in 5 days13 November, 20225 Sep 2022 Wockhardt receives affirmation in credit ratings from CARE5 September, 202226 Aug 2022 Will restructuring US biz turnaround this pharma player?26 August, 202220 Aug 2022 Wockhardt ties up with various partners to roll out products in US market16 August, 202216 Aug 2022 Wockhardt initiates phase-III clinical study of new antibiotic candidate16 August, 2022
